The treatment of patients with chronic hepatitis C virus infection has evolved during the last decade from interferon monotherapy to combination therapy with interferon and ribavirin. National and international guidelines recommend either 6 or 12 months of interferon/ribavirin combination therapy depending on the pre-treatment virological status of the patient. However, the choice for second-line treatment of patients who do not achieve sustained viral clearance with combination therapy has yet to be defined. This commentary examines previously published studies of the use of consensus interferon for hepatitis C virus infected patients. The characteristics of the treated populations and response to treatment are examined. The current and potential roles for this type of interferon in the treatment of hepatitis C virus infection are considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00042737-200205000-00001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
405 nm violet-blue light inactivates hepatitis C cell culture virus (HCVcc) in ex vivo human platelet concentrates and plasma.
Sci Rep
December 2024
Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, 20993, USA.
Added safety measures coupled with the development and use of pathogen reduction technologies (PRT) significantly reduces the risk of transfusion-transmitted infections (TTIs) from blood products. Current approved PRTs utilize chemical and/or UV-light based inactivation methods. While the effectiveness of these PRTs in reducing pathogens are well documented, these can cause tolerable yet unintended consequences on the quality and efficacy of the transfusion products.
View Article and Find Full Text PDFExpression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma.
Sci Rep
December 2024
Department of Gastroenterology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China.
Immune checkpoint inhibitor (ICI) therapy is the new standard treatment for advanced or metastatic hepatocellular carcinoma (HCC); however, many patients still fail to respond. This study explored the expression and prognosis of programmed death ligand 1 (PD-L1), cluster of differentiation 24 (CD24), and cluster of differentiation 47 (CD47) in patients with hepatitis B virus-associated HCC (HBV-associated HCC). We analyzed sequencing data from the Cancer Genome Atlas (TCGA) and investigated the expression of PD-L1, CD24, and CD47 in HBV-associated HCC patients by immunohistochemistry and their relationship with prognosis and clinicopathological factors.
View Article and Find Full Text PDFEconomic evaluation of tenofovir disoproxil fumarate prophylaxis to prevent mother-to-child transmission of Hepatitis B virus infection: evidence from a lower-middle income country.
BMC Health Serv Res
December 2024
Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, 10400, Thailand.
No cost-effectiveness information of preventive strategies for mother-to-child transmission (MTCT) of hepatitis B virus (HBV) has existed for policy decision making. This study aimed to compare the cost-effectiveness of alternative strategies to prevent MTCT of HBV in Vietnam. Cost-utility analysis using a hybrid decision-tree and Markov model were performed from healthcare system and societal perspectives.
View Article and Find Full Text PDFViral infections in celiac disease: what should be considered for better management.
Clin Exp Med
December 2024
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Following a gluten-free diet (GFD) is known as the main effective therapy available for celiac disease (CD) patients, which in some cases is not enough to heal all patients presentations completely. Accordingly, emerging researchers have focused on finding novel therapeutic/preventive strategies for this disorder. Moreover, previous studies have shown that celiac patients, especially untreated subjects, are at increased risk of developing viral and bacterial infections, which can become a challenge for the clinician.
View Article and Find Full Text PDFDisease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection.
CPT Pharmacometrics Syst Pharmacol
December 2024
Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!